Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

Jae-Yong Kwak

Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

Jae-Yong Kwak

Department of Medicine

Research output: Contribution to journal › Journal article › peer-review

Original language	Korean
Journal	British Journal of Haematology
State	Published - 2020.04.1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{897f18b19df940a9a3445ec1bbb1608e,

title = "Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)",

author = "Jae-Yong Kwak",

year = "2020",

month = apr,

day = "1",

language = "Korean",

journal = "British Journal of Haematology",

issn = "0007-1048",

}